[Pharmacological approaches in immuno-rhumatology].
Biologics have proven to be an effective treatment option for adults with rheumatoid           arthritis but their use in clinical practice may be limited by concerns over severe side           effects and cost. Pharmacology and development of biomarkers could help to optimize the           use of biologics in clinical practice.          Biomarkers are surrogate markers and include all diagnostic tests, imaging and           technologies and any other objective measure of a person's health status and all           pharmacodiagnostic tests.          Several studies evaluated interest of biomarkers in RA patients treated with biologics:           1- to optimize doses and frequency of drug administration; 2- to predict response to           treatment; 3- to predict tolerance of biologics; 4- to monitor patient who stopped           treatment and are in remission, and predict new RA flare.
Centre Hospitalier Universitaire, Montpellier, France. s-fabre@chu-montpellier.fr
Sylvie
S
Fabre
D000906:Antibodies / Q000032:analysis; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D001688:Biological Products / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015415:Biomarkers; D003362:Cost-Benefit Analysis; D005544:Forecasting; D006801:Humans; D000069283:Rituximab; D016896:Treatment Outcome
D000906:Antibodies; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D001688:Biological Products; D015415:Biomarkers; D000069283:Rituximab